pufa 20:2 c

PUFA 20:2 c, scientifically named cis‑11,14‑eicosadienoic acid, is a polyunsaturated fatty acid (PUFA) belonging to the omega‑6 family of dietary fats. PUFAs are defined by the presence of two or more cis double bonds in their carbon chain, and in the case of PUFA 20:2 c, there are two double bonds at the 11th and 14th carbon positions on a 20‑carbon backbone. The omega‑6 designation refers to the position of the first double bond relative to the methyl (omega) end of the molecule, which influences its metabolic fate and role in human physiology. PUFA 20:2 c is a relatively minor constituent of dietary fats, present at low levels in certain animal tissues, seed oils, nuts, and processed foods that include mixed fats. It is not considered an essential fatty acid on its own because the human body can derive necessary long‑chain PUFAs from more abundant precursors such as linoleic acid (LA), which is an essential fatty acid and must be obtained through the diet. However, PUFA 20:2 c still contributes to the overall PUFA pool in foods and participates in lipid metabolism as part of complex dietary fat mixtures.

As part of the polyunsaturated fatty acids class, PUFA 20:2 c contributes to general lipid nutrition and cellular functions. PUFAs are vital for the structure and function of cell membranes, maintaining membrane fluidity and flexibility, which in turn affects receptor function, nutrient transport, and cell signaling. Omega‑6 PUFAs like cis‑11,14‑eicosadienoic acid are metabolized through desaturation and elongation pathways to longer chain fatty acids that serve as precursors for bioactive lipid mediators known as eicosanoids. These signaling molecules, which include prostaglandins and leukotrienes, play roles in inflammation modulation, vasomotor tone, and immune responses. While PUFA 20:2 c itself is a minor dietary component, its presence in cell membrane phospholipids can influence the balance of omega‑6 derived mediators, which are part of intricate pro‑ and anti‑inflammatory pathways. Epidemiological evidence indicates that diets higher in PUFAs—particularly omega‑6 and omega‑3 PUFAs collectively—are associated with lower risks of cardiovascular disease and type 2 diabetes when they replace saturated fats or refined carbohydrates in the diet, suggesting beneficial effects on lipid metabolism and cardiometabolic health. Although much of this evidence focuses on major PUFAs like linoleic acid and arachidonic acid rather than cis‑11,14‑eicosadienoic acid specifically, the general mechanisms apply: PUFAs support structural integrity of membranes, contribute to lipid signaling pathways, and may influence systemic inflammation. Emerging research on minor PUFAs such as 20:2 c suggests that even these less abundant fatty acids can interact with inflammatory processes, but robust human clinical evidence remains limited. Overall, consuming a balanced mix of dietary fats rich in diverse PUFAs supports normal physiological functions.

Unlike major essential fatty acids such as linoleic acid (LA, an omega‑6) and alpha‑linolenic acid (ALA, an omega‑3), there are no official dietary reference intakes or recommended daily allowances established specifically for PUFA 20:2 c. Nutritional authorities such as the NIH Office of Dietary Supplements provide recommendations for total polyunsaturated fatty acid intake or for essential PUFAs but not for each individual minor PUFA variant. Total PUFA intake recommendations generally emphasize replacing saturated fats with unsaturated fats, including both omega‑6 and omega‑3 sources, to achieve a healthy dietary fat profile. The absence of a specific requirement for PUFA 20:2 c reflects its status as a minor component of dietary fats rather than an essential nutrient per se. However, this fatty acid contributes to the pool of dietary PUFAs, and ensuring adequate intake of diverse unsaturated fats supports overall lipid nutrition. Factors that influence PUFA needs include age, sex, metabolic health status, and overall dietary fat composition. For instance, higher intake of linoleic acid—the precursor for many omega‑6 derived fatty acids—supports endogenous synthesis of longer chain PUFAs, although conversion efficiency in humans is limited. In practical terms, focusing on dietary patterns rich in a variety of PUFAs naturally ensures intake of 20:2 c along with more abundant PUFAs. This means incorporating sources such as nuts, seeds, vegetable oils, and lean meats where cis‑11,14‑eicosadienoic acid is present in trace amounts alongside other beneficial fatty acids.

Because PUFA 20:2 c is not classified as an essential fatty acid and constitutes a minor component of the dietary PUFA pool, there are no defined deficiency symptoms specific to this fatty acid alone. Essential fatty acid deficiency, which can occur when the diet is severely low in both linoleic acid and alpha‑linolenic acid, presents with well‑characterized clinical signs such as scaly dermatitis, poor wound healing, hair loss, impaired growth in children, and altered immune function. In such cases, the lack of essential precursors prevents the synthesis of key long‑chain PUFAs and their derivatives. In contrast, a deficiency of PUFA 20:2 c specifically has not been documented in clinical literature because humans obtain sufficient quantities through typical dietary fat intake patterns, and the body can derive adequate lipid building blocks from more abundant essential PUFAs. At a systemic level, suboptimal PUFA status more generally may contribute to altered membrane composition, inflammatory responses, and metabolic dysregulation, but isolating the role of a single minor fatty acid like 20:2 c in these processes is not currently possible with existing evidence. Therefore, signs attributed to broader PUFA insufficiency reflect deficits in essential PUFAs rather than this specific fatty acid.

PUFA 20:2 c is found primarily as a minor component in mixed dietary fats rather than as a major fatty acid in specific foods. Based on nutrient composition databases for eicosadienoic acid (20:2 n‑6 c,c), notable food sources include fatty animal products, certain nuts, seeds, and mixed fat foods. For example, raw pork fat contains approximately 445 mg of PUFA 20:2 c per 100 g serving, and cooked bacon fat contains about 442 mg per 100 g. Dried pine nuts offer around 404 mg per 100 g, while ground mustard seed provides roughly 250 mg per 100 g. These values illustrate that animal fats and higher‑fat plant seeds are among the most concentrated sources of this fatty acid. Other meat products such as pork sausage, ham, and various processed pork items also contain appreciable amounts of 20:2 c in their fat fraction. Egg yolk powder contains trace amounts, as do certain fish species such as swordfish and salmon at much lower levels. It is important to note that these foods contribute many other fatty acids as well, making them part of a spectrum of dietary lipids rather than isolated 20:2 c sources. Regular consumption of a balanced diet that includes lean meats, nuts, seeds, and plant oils ensures intake of PUFA 20:2 c along with the broader array of polyunsaturated fats needed for general health.

Like other long‑chain fatty acids, PUFA 20:2 c is absorbed in the small intestine following digestion by pancreatic lipases and incorporation into micelles with the help of bile acids. Once absorbed, fatty acids are re‑esterified into triglycerides and packaged into chylomicrons for transport through the lymphatic system to systemic circulation. The presence of dietary fat facilitates this process, as bile and micelle formation are essential for efficient absorption of hydrophobic fatty acids. Bioavailability of PUFAs can be influenced by overall dietary fat composition, the presence of other nutrients such as dietary fiber (which may bind bile acids and reduce absorption efficiency), and the balance of omega‑6 to omega‑3 fatty acids in the diet. Additionally, the form of the fatty acid—whether free fatty acid, triglyceride, or phospholipid—affects its incorporation efficiency into lipoprotein particles and subsequent uptake by tissues. Factors such as aging, digestive disorders, or use of bile acid sequestrants can also affect absorption efficiency. Therefore, consuming PUFA 20:2 c as part of mixed dietary fats in meals with other lipids optimizes its uptake and integration into lipid pools.

There are currently no supplements marketed specifically for PUFA 20:2 c due to its status as a minor dietary fatty acid and lack of evidence for distinct health benefits that would warrant targeted supplementation. Most fatty acid supplements focus on major PUFAs with established health roles, such as omega‑3 fish oil (EPA and DHA) or plant‑based ALA supplements. Given the absence of deficiency syndromes specific to PUFA 20:2 c and the fact that typical diets provide adequate amounts incidentally, supplementing this fatty acid alone is neither necessary nor supported by clinical evidence. However, ensuring sufficient overall PUFA intake through dietary patterns that include diverse unsaturated fat sources can be beneficial for general health. Individuals with conditions that impair fat absorption or digestion, such as certain gastrointestinal disorders, may benefit from working with healthcare professionals to address overall fatty acid nutrition, including essential and long‑chain PUFAs, rather than focusing on specific minor components like 20:2 c.

There is no established tolerable upper intake level (UL) or documented toxicity specific to PUFA 20:2 c. Since this fatty acid is consumed as part of broader dietary fats, adverse effects associated with high intake are more likely linked to excessive consumption of total dietary fat or imbalanced omega‑6 to omega‑3 ratios rather than toxicity of the fatty acid itself. In general, extremely high intake of omega‑6 PUFAs relative to omega‑3s has been hypothesized to promote pro‑inflammatory states when not balanced by adequate omega‑3 intake, but evidence for harm is mixed and context dependent, with overall cardiometabolic risk influenced by total diet quality. Therefore, prioritizing balanced intake of PUFAs within the context of overall healthy dietary patterns is more important than concern about toxicity of specific minor fatty acids like 20:2 c.

There are no specific documented drug interactions for PUFA 20:2 c itself. Generally, high intake of PUFAs can influence blood lipid profiles and, when consumed in supplement form (e.g., omega‑3 supplements), may have mild effects on anticoagulant medications such as warfarin or antiplatelet drugs by modestly affecting platelet aggregation. However, these effects are associated with major long‑chain PUFAs at supplemental doses far exceeding typical dietary intake rather than minor components like cis‑11,14‑eicosadienoic acid.